Thrombocytosis as a response to high interleukin-6 levels in cGMP-dependent protein kinase i mutant mice

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 33, Issue 8, 2013, Pages 1820-1828

  Zhang, Lin ^a,b   Lukowski, Robert ^c,d   Gaertner, Florian ^a   Lorenz, Michael ^a   Legate, Kyle R ^a,e   Domes, Katrin ^c   Angermeier, Elisabeth ^c   Hofmann, Franz ^c   Massberg, Steffen ^a,c,f,g  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY OF TÜBINGEN   (Germany)

^e UNIVERSITY OF MUNICH   (Germany)

^f Franz Volhard Klinik   (Germany)

^g Munich Heart Alliance   (Germany)

Author keywords

cGMP dependent protein kinase type I; Interleukin 6; Thrombopoiesis

Indexed keywords

CYCLIC GMP DEPENDENT PROTEIN KINASE 1; INTERLEUKIN 6; THROMBOCYTE FACTOR 4;

ARTICLE; BONE MARROW; BONE MARROW CELL; CHIMERA; CYTOMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMATOPOIETIC SYSTEM; IN VITRO STUDY; IN VIVO STUDY; MEGAKARYOCYTE; MEGAKARYOPOIESIS; MOUSE; NONHUMAN; PHENOTYPE; POLYPLOIDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; THROMBOCYTE COUNT; THROMBOCYTOPOIESIS; THROMBOCYTOSIS;

CGMP-DEPENDENT PROTEIN KINASE TYPE I; INTERLEUKIN-6; THROMBOPOIESIS;

ANIMALS; BLOOD PLATELETS; BONE MARROW CELLS; CYCLIC GMP-DEPENDENT PROTEIN KINASE TYPE I; HEMATOPOIESIS; HEMOSTASIS; INTERLEUKIN-6; MEGAKARYOCYTES; MICE; MICE, KNOCKOUT; PHENOTYPE; PLATELET COUNT; SIGNAL TRANSDUCTION; THROMBOCYTOSIS;

EID: 84881023496     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.113.301507     Document Type: Article

References (44)

1. Schafer AI. Thrombocytosis. N Engl J Med. 2004;350: 1211-1219.
2. Kaushansky K. Thrombopoietin and the hematopoietic stem cell. Ann N Y Acad Sci. 2005;1044: 139-141.
3. Deutsch VR, Tomer A. Megakaryocyte development and platelet production. Br J Haematol. 2006;134: 453-466.
4. Kaushansky K. The molecular mechanisms that control thrombopoiesis. J Clin Invest. 2005;115: 3339-3347.
5. Debili N, Coulombel L, Croisille L, Katz A, Guichard J, Breton-Gorius J, Vainchenker W. Characterization of a bipotent erythro-megakaryocytic progenitor in human bone marrow. Blood. 1996;88: 1284-1296.
6. Long MW, Gragowski LL, Heffner CH, Boxer LA. Phorbol diesters stimulate the development of an early murine progenitor cell. The burst-forming unit-megakaryocyte. J Clin Invest. 1985;76: 431-438.
7. Briddell RA, Brandt JE, Straneva JE, Srour EF, Hoffman R. Characterization of the human burst-forming unit-megakaryocyte. Blood. 1989;74: 145-151.
8. McLeod DL, Shreve MM, Axelrad AA. Induction of megakaryocyte colonies with platelet formation in vitro. Nature. 1976;261: 492-494.
9. Vainchenker W, Bouguet J, Guichard J, Breton-Gorius J. Megakaryocyte colony formation from human bone marrow precursors. Blood. 1979;54: 940-945.
10. Schulze H, Shivdasani RA. Molecular mechanisms of megakaryocyte differentiation. Semin Thromb Hemost. 2004;30: 389-398.
11. Radley JM, Haller CJ. The demarcation membrane system of the megakaryocyte: a misnomer? Blood. 1982;60: 213-219.
12. Zhang L, Orban M, Lorenz M, et al. A novel role of sphingosine 1-phosphate receptor s1pr1 in mouse thrombopoiesis. J Exp Med. 2012;209: 2165-2181.
13. Massberg S, Sausbier M, Klatt P, Bauer M, Pfeifer A, Siess W, Fässler R, Ruth P, Krombach F, Hofmann F. Increased adhesion and aggregation of platelets lacking cyclic guanosine 3',5'-monophosphate kinase I. J Exp Med. 1999;189: 1255-1264.
14. Antl M, von Brühl ML, Eiglsperger C, Werner M, Konrad I, Kocher T, Wilm M, Hofmann F, Massberg S, Schlossmann J. IRAG mediates NO/ cGMP-dependent inhibition of platelet aggregation and thrombus formation. Blood. 2007;109: 552-559.
15. Danielewski O, Schultess J, Smolenski A. The NO/cGMP pathway inhibits Rap 1 activation in human platelets via cGMP-dependent protein kinase I. Thromb Haemost. 2005;93: 319-325.
16. Begonja AJ, Gambaryan S, Schulze H, Patel-Hett S, Italiano JE Jr, Hartwig JH, Walter U. Differential roles of cAMP and cGMP in megakaryocyte maturation and platelet biogenesis. Exp Hematol. 2013;41:91-101.e4.
17. Francis SH, Busch JL, Corbin JD, Sibley D. cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action. Pharmacol Rev. 2010;62: 525-563.
18. Zaccolo M, Movsesian MA. cAMP and cGMP signaling cross-talk: role of phosphodiesterases and implications for cardiac pathophysiology. Circ Res. 2007;100: 1569-1578.
19. Feil R, Lohmann SM, de Jonge H, Walter U, Hofmann F. Cyclic GMPdependent protein kinases and the cardiovascular system: insights from genetically modified mice. Circ Res. 2003;93: 907-916.
20. Li Z, Xi X, Gu M, Feil R, Ye RD, Eigenthaler M, Hofmann F, Du X. A stimulatory role for cGMP-dependent protein kinase in platelet activation. Cell. 2003;112: 77-86.
21. Wang GR, Zhu Y, Halushka PV, Lincoln TM, Mendelsohn ME. Mechanism of platelet inhibition by nitric oxide: in vivo phosphorylation of thromboxane receptor by cyclic GMP-dependent protein kinase. Proc Natl Acad Sci U S A. 1998;95: 4888-4893.
22. Weber S, Bernhard D, Lukowski R, Weinmeister P, Wörner R, Wegener JW, Valtcheva N, Feil S, Schlossmann J, Hofmann F, Feil R. Rescue of cGMP kinase I knockout mice by smooth muscle specific expression of either isozyme. Circ Res. 2007;101: 1096-1103.
23. Tiedt R, Schomber T, Hao-Shen H, Skoda RC. Pf4-Cre transgenic mice allow the generation of lineage-restricted gene knockouts for studying megakaryocyte and platelet function in vivo. Blood. 2007;109: 1503-1506.
24. Pfeifer A, Klatt P, Massberg S, Ny L, Sausbier M, Hirneiss C, Wang GX, Korth M, Aszódi A, Andersson KE, Krombach F, Mayerhofer A, Ruth P, Fässler R, Hofmann F. Defective smooth muscle regulation in cGMP kinase I-deficient mice. EMBO J. 1998;17: 3045-3051.
25. Lutz SZ, Hennige AM, Feil S, Peter A, Gerling A, Machann J, Kröber SM, Rath M, Schürmann A, Weigert C, Häring HU, Feil R. Genetic ablation of cGMP-dependent protein kinase type I causes liver inflammation and fasting hyperglycemia. Diabetes. 2011;60: 1566-1576.
26. Le Huu D, Matsushita T, Jin G, Hamaguchi Y, Hasegawa M, Takehara K, Fujimoto M. IL-6 blockade attenuates the development of murine sclerodermatous chronic graft-versus-host disease. J Invest Dermatol. 2012;132: 2752-2761.
27. Navarro S, Debili N, Le Couedic JP, Klein B, Breton-Gorius J, Doly J, Vainchenker W. Interleukin-6 and its receptor are expressed by human megakaryocytes: in vitro effects on proliferation and endoreplication. Blood. 1991;77: 461-471.
28. Ishibashi T, Kimura H, Shikama Y, Uchida T, Kariyone S, Hirano T, Kishimoto T, Takatsuki F, Akiyama Y. Interleukin-6 is a potent thrombopoietic factor in vivo in mice. Blood. 1989;74: 1241-1244.
29. Hill RJ, Warren MK, Levin J. Stimulation of thrombopoiesis in mice by human recombinant interleukin 6. J Clin Invest. 1990;85: 1242-1247.
30. Riedemann NC, Neff TA, Guo RF, Bernacki KD, Laudes IJ, Sarma JV, Lambris JD, Ward PA. Protective effects of IL-6 blockade in sepsis are linked to reduced C5a receptor expression. J Immunol. 2003;170: 503-507.
31. Rochman I, Paul WE, Ben-Sasson SZ. IL-6 increases primed cell expansion and survival. J Immunol. 2005;174: 4761-4767.
32. Zhang J, Varas F, Stadtfeld M, Heck S, Faust N, Graf T. CD41-YFP mice allow in vivo labeling of megakaryocytic cells and reveal a subset of platelets hyperreactive to thrombin stimulation. Exp Hematol. 2007;35: 490-499.
33. Pozner RG, Negrotto S, D'Atri LP, Kotler ML, Lazzari MA, Gomez RM, Schattner M. Prostacyclin prevents nitric oxide-induced megakaryocyte apoptosis. Br J Pharmacol. 2005;145: 283-292.
34. Battinelli E, Willoughby SR, Foxall T, Valeri CR, Loscalzo J. Induction of platelet formation from megakaryocytoid cells by nitric oxide. Proc Natl Acad Sci U S A. 2001;98: 14458-14463.
35. Schattner M, Pozner RG, Engelberger I, Gorostizaga A, Maugeri N, Gomez R, Pasqualini A, Torres O, Lazzari MA. Effect of nitric oxide on megakaryocyte growth induced by thrombopoietin. J Lab Clin Med. 2001;137: 261-269.
36. Battinelli E, Loscalzo J. Nitric oxide induces apoptosis in megakaryocytic cell lines. Blood. 2000;95: 3451-3459.
37. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med. 1993;329: 2002-2012.
38. Ouaaz F. Nitric oxide in human haematopoiesis. Res Immunol. 1995;146: 678-681.
39. Gkaliagkousi E, Ferro A. Nitric oxide signalling in the regulation of cardiovascular and platelet function. Front Biosci. 2011;16: 1873-1897.
40. Mitschke MM, Hoffmann LS, Gnad T, Scholz D, Kruithoff K, Mayer P, Haas B, Sassmann A, Pfeifer A, Kilic A. Increased cGMP promotes healthy expansion and browning of white adipose tissue. FASEB J. 2013;27: 1621-1630.
41. Ishibashi T, Kimura H, Uchida T, Kariyone S, Friese P, Burstein SA. Human interleukin 6 is a direct promoter of maturation of megakaryocytes in vitro. Proc Natl Acad Sci U S A. 1989;86: 5953-5957.
42. Singh AK, Spiessberger B, Zheng W, Xiao F, Lukowski R, Wegener JW, Weinmeister P, Saur D, Klein S, Schemann M, Krueger D, Seidler U, Hofmann F. Neuronal cGMP kinase I is essential for stimulation of duodenal bicarbonate secretion by luminal acid. FASEB J. 2012;26: 1745-1754.
43. Avecilla ST, Hattori K, Heissig B, et al. Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis. Nat Med. 2004;10: 64-71.
44. Junt T, Schulze H, Chen Z, Massberg S, Goerge T, Krueger A, Wagner DD, Graf T, Italiano JE Jr, Shivdasani RA, von Andrian UH. Dynamic visualization of thrombopoiesis within bone marrow. Science. 2007;317: 1767-1770.